Lundbeck research director after double fiasco: We have much more interesting assets to work on

Although research director Johan Luthman is disappointed that Parkinson's drug foliglurax has performed so badly in clinical trials that the project is being shut down, he still sees lots of potential in the newly-purchased Abide portfolio - though this has also included one fiasco.

Photo: PR / Lundbeck

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles